NO2002003I2 - Ferukarbotran og L (+)- melkesyre - Google Patents

Ferukarbotran og L (+)- melkesyre

Info

Publication number
NO2002003I2
NO2002003I2 NO2002003C NO2002003C NO2002003I2 NO 2002003 I2 NO2002003 I2 NO 2002003I2 NO 2002003 C NO2002003 C NO 2002003C NO 2002003 C NO2002003 C NO 2002003C NO 2002003 I2 NO2002003 I2 NO 2002003I2
Authority
NO
Norway
Prior art keywords
ultrafine particles
ferucarbotran
lactic acid
composition
polysaccharide
Prior art date
Application number
NO2002003C
Other languages
English (en)
Original Assignee
Meito Sangyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12001420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2002003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meito Sangyo Kk filed Critical Meito Sangyo Kk
Publication of NO2002003I2 publication Critical patent/NO2002003I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
    • G01N2400/22—Dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Soft Magnetic Materials (AREA)
  • Compounds Of Iron (AREA)
  • Hard Magnetic Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NO2002003C 1991-01-19 2002-05-16 Ferukarbotran og L (+)- melkesyre NO2002003I2 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1951291 1991-01-19

Publications (1)

Publication Number Publication Date
NO2002003I2 true NO2002003I2 (no) 2005-04-04

Family

ID=12001420

Family Applications (2)

Application Number Title Priority Date Filing Date
NO923584A NO305636B1 (no) 1991-01-19 1992-09-15 Sammensetning inneholdende ultrafine magnetiske metalloksydpartikler, samt MRI-kontrastmiddel derav
NO2002003C NO2002003I2 (no) 1991-01-19 2002-05-16 Ferukarbotran og L (+)- melkesyre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO923584A NO305636B1 (no) 1991-01-19 1992-09-15 Sammensetning inneholdende ultrafine magnetiske metalloksydpartikler, samt MRI-kontrastmiddel derav

Country Status (13)

Country Link
US (1) US5328681A (no)
EP (1) EP0525199B2 (no)
JP (1) JP2921984B2 (no)
AT (1) ATE179894T1 (no)
AU (1) AU652804B2 (no)
CA (1) CA2078679C (no)
DE (2) DE69229150T3 (no)
DK (1) DK0525199T4 (no)
ES (1) ES2131067T5 (no)
LU (1) LU91003I2 (no)
NL (1) NL300088I1 (no)
NO (2) NO305636B1 (no)
WO (1) WO1992012735A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156706T1 (de) * 1993-03-17 1997-08-15 Silica Gel Gmbh Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben
EP0741581A1 (en) * 1994-01-28 1996-11-13 Nycomed Imaging As Oral magnetic particle formulation
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
DE19509694A1 (de) * 1995-03-08 1996-09-19 Schering Ag Verwendung von Magnetiten zur Bestimmung der Perfusion von menschlichem Gewebe mittels MR-Diagnostik
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
CA2242647A1 (en) 1996-01-10 1997-07-17 Amersham Health As Contrast media
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
FR2749082B1 (fr) * 1996-05-24 1998-06-26 Bio Merieux Particules superparamagnetiques et monodispersees
CN1151846C (zh) 1996-08-05 2004-06-02 舍林公开股份有限公司 核磁共振断层扫描成像用造影剂的制备方法
US6815063B1 (en) 1996-11-16 2004-11-09 Nanomagnetics, Ltd. Magnetic fluid
GB2319253A (en) 1996-11-16 1998-05-20 Eric Leigh Mayes Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles
US6713173B2 (en) * 1996-11-16 2004-03-30 Nanomagnetics Limited Magnetizable device
US20060003163A1 (en) * 1996-11-16 2006-01-05 Nanomagnetics Limited Magnetic fluid
US6986942B1 (en) 1996-11-16 2006-01-17 Nanomagnetics Limited Microwave absorbing structure
US6725078B2 (en) * 2000-01-31 2004-04-20 St. Louis University System combining proton beam irradiation and magnetic resonance imaging
US7179660B1 (en) 2000-03-06 2007-02-20 Dade Behring Marburg Gmbh Carriers coated with polysaccharides, their preparation and use
US6743395B2 (en) * 2000-03-22 2004-06-01 Ebara Corporation Composite metallic ultrafine particles and process for producing the same
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
DE10154016B4 (de) * 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
AU2003266501A1 (en) * 2002-08-16 2004-03-03 Admetec Co., Ltd. Heating method and heating apparatus therefor
TW200423949A (en) 2003-01-31 2004-11-16 Otsuka Pharma Co Ltd Auxiliary agent used for the cancer medical treatment by dielectric heating, and cancer medical treatment method
FR2861994A1 (fr) * 2003-11-12 2005-05-13 Guerbet Sa Nouvel agent de diagnostic pour l'irm dans les pathologies impliquant des proteinases
CA2749057A1 (en) 2004-02-20 2005-09-09 University Of Florida Research Foundation, Inc. System for delivering conformal radiation therapy while simultaneously imaging soft tissue
JP3822229B2 (ja) * 2004-05-27 2006-09-13 松下電器産業株式会社 基板上への微粒子配列体の形成方法
WO2006051732A1 (ja) * 2004-11-10 2006-05-18 Konica Minolta Medical & Graphic, Inc. 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
JP5354566B2 (ja) * 2008-07-25 2013-11-27 名糖産業株式会社 カチオン性多糖磁性粒子複合体
CA2738711C (en) * 2008-09-29 2014-01-28 Vifor (International) Ag Receptacle and method for storing and supplying a liquid and a liquid medical preparation
IT1398263B1 (it) 2010-03-04 2013-02-22 Monzani Nanoparticelle magnetiche di ossido di ferro a dimensione controllata per la diagnosi ed il trattamento di neoplasie avanzate e metastatiche
DE102011112898A1 (de) 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
US10561861B2 (en) 2012-05-02 2020-02-18 Viewray Technologies, Inc. Videographic display of real-time medical treatment
US9889318B2 (en) 2012-10-26 2018-02-13 Viewray Technologies, Inc. Assessment and improvement of treatment using imaging of physiological responses to radiation therapy
JP6535857B2 (ja) * 2015-03-16 2019-07-03 国立大学法人 岡山大学 γ−酸化鉄の製造方法
EP3423153B1 (en) 2016-03-02 2021-05-19 ViewRay Technologies, Inc. Particle therapy with magnetic resonance imaging
RU2019121943A (ru) 2016-12-13 2021-01-15 Вьюрэй Текнолоджиз, Инк. Системы и способы лучевой терапии
JP7127126B2 (ja) 2017-12-06 2022-08-29 ビューレイ・テクノロジーズ・インコーポレイテッド 放射線治療のシステム、方法およびソフトウェア
US11209509B2 (en) 2018-05-16 2021-12-28 Viewray Technologies, Inc. Resistive electromagnet systems and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001288A (en) * 1965-09-15 1977-01-04 Howard S. Gable Magnetic organo-iron compounds
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
SE463651B (sv) * 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
ATE82500T1 (de) * 1984-06-22 1992-12-15 Richard L Veech Elektrolytloesungen und deren (in vivo) verwendung.
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
JPH0616444B2 (ja) * 1986-03-05 1994-03-02 鹿島石油株式会社 磁性ミクロスフエアの製造方法
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5160726A (en) * 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
SE8704157L (sv) * 1987-10-26 1989-04-27 Carbomatrix Ab C O Ulf Schroed Superparamagnetiska partiklar och foerfarande foer framstaellning daerav samt anvaendning
US5114703A (en) * 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体

Also Published As

Publication number Publication date
EP0525199B2 (en) 2004-04-14
ATE179894T1 (de) 1999-05-15
JP2921984B2 (ja) 1999-07-19
EP0525199A1 (en) 1993-02-03
NO923584L (no) 1992-11-12
NO923584D0 (no) 1992-09-15
LU91003I2 (en) 2003-03-24
EP0525199B1 (en) 1999-05-12
AU652804B2 (en) 1994-09-08
US5328681A (en) 1994-07-12
AU1168992A (en) 1992-08-27
DE69229150T3 (de) 2005-01-05
DE69229150D1 (de) 1999-06-17
DE10199065I2 (de) 2004-09-23
NL300088I1 (nl) 2002-07-01
DK0525199T3 (da) 1999-11-01
CA2078679C (en) 2006-12-05
CA2078679A1 (en) 1992-07-20
NO305636B1 (no) 1999-07-05
DE10199065I1 (de) 2002-02-21
DK0525199T4 (da) 2004-06-01
WO1992012735A1 (fr) 1992-08-06
DE69229150T2 (de) 1999-09-30
ES2131067T3 (es) 1999-07-16
EP0525199A4 (en) 1994-08-17
ES2131067T5 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
NO2002003I2 (no) Ferukarbotran og L (+)- melkesyre
DE10199064I1 (de) Oxidierte Zusammensetzung enthaltend ein wasserloesliches Carboxypolysaccharid und magnetisches Eisenoxid
DE68927189D1 (de) Arzneimittel, die Lanthionin enthaltenden Bacteriozin enthalten, zur Verwendung als Bakterizide
RU93058607A (ru) Устройство для переноса ионов, в частности протонов
IT8323311A0 (it) Particolarmente per l'infusione di dispositivo e procedimento per medicine od altri liquidi medicali l'infusione di medicazioni, in un organismo vivente.
DE3650644D1 (de) Magnetische Polymerpartikeln
Bullen et al. The bacteriostatic effect of serum on Pasteurella septica and is abolition by iron compounds
PT83825A (de) Mittel zur bestimmung von peroxidase-aktivitaet mit stabilisator verfahren zur herstellung und seine verwendung
ES2062241T3 (es) Metodo de purificacion de la albumina serica humana.
ZA883599B (en) Mixed crystals of insulin and insulin derivatives,a process for the preparation of these mixed crystals,pharmaceutical agents containing these mixed crystals,and the use thereof for the treatment of diabetes mellitus
ATE88738T1 (de) Waesserige zusammensetzungen, welche eine kationische verbindung und xanthangummi enthalten.
DE68906061D1 (de) Mindestens eine peroxydische substanz und ein uebergangsmetallsalz enthaltende feste galenische formen.
ATE89719T1 (de) Aeusserlich anzuwendende amusulosin enthaltende arzneizubereitung.
EP0355453A3 (en) Use of 3-hydroxybutyric acid as an energy source
US3522347A (en) Toxoid compositions
Gritsenko et al. The effect of the Ti (IV)-citrate complex on Staphylococcus aureus growth and biofilm formation
Mellor et al. Effects of antibiotic treatment on the composition of sheep foetal fluids
EP0373388A3 (de) Penemderivate und Verfahren zu ihrer Herstellung
Danilov et al. Concentration of erythrocyte-based magnetic carriers in the vascular bed
UA9626A (uk) Спосіб діагностики вперше виявленого туберкульозу легень
Antalek et al. Infection in the nursing home
Mandel A New Anticoagulant, Vitamin B6: Results of a Comparative Study with Hydroxychloroquine Sulphate, in vitro
George Hydrocephalus shunt infections: R. Bayston. London: Chapman & Hall (1989), pp. 160,£ 22.50. ISBN 0412312409
Bauminger Some biological applications of the Moessbauer effect in blood diseases, like thalassemia and malaria
Suarez Septicemia by Listeria monocytogenes in the newborn(report of a case).